Breast Cancer Reserach Studies at John Stoddard Cancer Center

UnityPoint Clinic Urgent Care - Altoona

00 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ingersoll

03 Patients
Waiting Now

Urgent Care - Ankeny

02 Patients
Waiting Now

Urgent Care - Lakeview

02 Patients
Waiting Now

Urgent Care - Merle Hay

01 Patients
Waiting Now

Urgent Care - Southglen

02 Patients
Waiting Now

Urgent Care - Urbandale

01 Patients
Waiting Now

Breast Cancer Research Studies

ERPR+ / HER2-

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer. 

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive, and HER2/NEU Negative Breast Cancer: E3 Breast Cancer Study - Evaluating Everolimus with Endocrine Therapy.

ADVANCED
E2112: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat / Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer.

TRIPLE NEGATIVE
BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer.

S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer &/or BRCA Mutation-Associated Breast Cancer.

BRCA 1/2 MUTATIONS & HER2-
B-55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High-Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.

NODE+ / HIGH RISK NODE - / HER2-
A011502: A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive HER2 Negative Breast Cancer: The ABC Trial.

POST NEOADJUVANT
A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.

B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

EA1131: A Randomized Phase III Post-Operative Trial of Platinum-Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy.

S1418: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.

CANCER CONTROL
A011404: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

CC004: Phase II Double Blind Dose-Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

WF-97116: A Phase 3 Placebo-Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

CANCER CARE DELIVERY RESEARCH
S1415CD: "TrACER": Trial Assessing CSF prescribing Effectiveness and Risk